Inhaled Furosemide for Transient Tachypnea of Newborn

Not Applicable

Completed

• Conditions: Respiratory Morbidity
• Interventions: Other: Placebo; Other: Furosemide

• Registration Number: NCT04397991
• Lead Sponsor: Makassed General Hospital

Brief Summary

This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-02
• Study First Submitted: 2020-05-18
• Study First Submitted QC: 2020-05-18
• Study First Posted: 2020-05-21
• Primary Completion: 2021-08-01
• Study Completion: 2021-08-01
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-28
• Last Update Posted: 2022-08-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• Neonates with 34+0-39+0 gestational age
• on the first day of life
• with the clinical diagnosis of Transient Tachypnoea
• need for CPAP >6 hours to obtain the oxygen saturation >92%

Exclusion Criteria

• Systemic infection
• Intubation and mechanical ventilation before Inclusion in the trail
• Malformation and any other disease with disturb of respiratory system

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Patients will receive nebulised 0.9% saline
Furosemide	Furosemide	Patients will receive nebulised furosemide

Primary Outcome Measures

Name	Time	Method
Percentage of patients with respiratory morbidity	24 hours	Neonatal respiratory morbidity will be assessed through oxygen saturation, respiratory rate and duration on Continuous positive airway pressure (CPAP)

Secondary Outcome Measures

Name	Time	Method
Length of hospital stay	15 days	Duration of hospital stay in days

Trial Locations

Locations (1)

Makassed General Hospital; 🇱🇧 Beirut, Lebanon